A hypoxic microfluidic organoid-on-a-chip system for studying the efficacy of metronidazole-modified nanomaterials against cholangiocarcinoma established within the chip

Key Points

• The research aims to evaluate the efficacy of metronidazole-modified nanomaterials in a hypoxic environment that mimics cholangiocarcinoma.
• Developed a microfluidic organoid-on-a-chip system
• Created a hypoxic tumor microenvironment
• Administered metronidazole-modified nanomaterials to cholangiocarcinoma organoids
• Analyzed drug efficacy in the defined TME
• Observed tumor growth reduction with metronidazole-modified nanomaterials
• Demonstrated improved drug sensitivity in the hypoxic microenvironment
• Identified significant changes in organoid viability and response to treatment